RNA, U6 small nuclear 820, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-820P profile across patient tissues and cancer cell-line models. RNU6-820P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNU6-820P is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, RNU6-820P RNA expression shows 6,709 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight DLBC, and ESCA as cancer lineages where RNU6-820P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-820P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-820P survival associations across molecular data types. RNU6-820P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-820P RNA expression–survival associations across cancer types. High RNU6-820P expression shows unfavorable associations in DLBC, READ, THCA, THYM and ESCA, but favorable associations in LAML. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RNU6-820P RNA expression.
This table summarizes RNU6-820P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-820P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-820P shows lower tumor expression in ESCA. The ESCA box plot shows higher RNU6-820P RNA expression in normal versus tumor tissue (log2 FC = −0.535, t-test p < 0.001).
This table shows molecular features associated with RNU6-820P in patient tissues and cancer cell lines. In patient samples, RNU6-820P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
